Skip to content

Safety and efficacy of sodium phosphate powder for intestinal preparation in people aged 50 to 70 years old

Safety and efficacy of sodium phosphate powder for intestinal preparation in individuals aged 50 to 70: a prospective, multicenter, randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095664
Enrollment
Unknown
Registered
2025-01-10
Start date
2023-12-22
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sodium phosphate powder group:Taking sodium phosphate powder for intestinal preparation
Polyethylene glycol group:Preparation of intestines by taking polyethylene glycol

Sponsors

Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age 50 to 70 years old, gender not limited; 2.No contraindications for colonoscopy examination, planned to undergo colonoscopy examination in the near future; 3.Agree to participate in this study;

Exclusion criteria

Exclusion criteria: 1. Patients with a history of colorectal surgery (resection of malignant tumors, resection of colorectal perforation, etc.); 2. Electrolyte imbalance, hemodialysis patients; 3. Patients with active lower gastrointestinal bleeding; 4. Patients with coagulation dysfunction; 5. Patients with severe primary diseases of the lungs, liver, kidneys, hematopoietic system, etc., and liver function ALT and AST exceeding 1.5 times the upper limit of the reference value, or Cr exceeding the upper limit of the reference value; 6. Merge other diseases that may affect the efficacy judgment or pose significant risks, such as acute phase of inflammatory bowel disease, colon cancer, intussusception, intestinal torsion, intestinal obstruction, peritonitis, ascites, refractory constipation, etc; 7. Patients with mental illness and severe neurological disorders; 8. Known patients with allergies to the test drug or control drug; 9. Participated in other clinical researchers within one month; 10. Researchers believe that there are other situations that are not suitable for inclusion, and patients are unwilling to join the group;

Design outcomes

Primary

MeasureTime frame
Bowel preparation qualification rate;

Secondary

MeasureTime frame
Adenoma detection rate;Adverse Effects Rate;

Countries

China

Contacts

Public ContactLei Wang

Nanjing Drum Tower Hospital The Affiliated Hosipital of Nanjing University Medical School

leiwang9631@nju.edu.cn+86 13851579216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 27, 2026